Amy Pomeroy
@amypomeroy.bsky.social
📤 23
📥 21
📝 13
computational cancer pharmacologist at UNC | modeling clinical trials of combination therapy
reposted by
Amy Pomeroy
12 months ago
New paper, with Amy Pomeroy! A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma now out in Blood Cancer Discovery:
doi.org/10.1158/2643...
#mathonc
#lymsm
#BloodCancer
1/n
loading . . .
A model of intra-tumor and inter-patient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Abstract. Models of tumor drug response have illuminated important concepts in oncology, but there remains a need for theory that combines intra-tumor and inter-patient heterogeneity to explain patien...
https://doi.org/10.1158/2643-3230.BCD-24-0230
1
3
2
I am so excited to share that our new paper is out! A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma Out in Blood Cancer Discovery
doi.org/10.1158/2643-3230.BCD-24-0230
#mathonc
#lymsm
#BloodCancer
1/n
loading . . .
A model of intra-tumor and inter-patient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Abstract. Models of tumor drug response have illuminated important concepts in oncology, but there remains a need for theory that combines intra-tumor and inter-patient heterogeneity to explain patien...
https://doi.org/10.1158/2643-3230.BCD-24-0230
12 months ago
1
7
4
reposted by
Amy Pomeroy
Association for Cancer Systems Biologists
about 1 year ago
An impressive result from their work - their model would have been able to predict from single treatment trials what would have happened in the combination trials
0
1
1
reposted by
Amy Pomeroy
Association for Cancer Systems Biologists
about 1 year ago
Dr. Amy Pomeroy is up next in our postdoc spotlight session telling us about their work on mechanistic modeling of combination therapy
doi.org/10.1101/2024...
1
3
2
you reached the end!!
feeds!
log in
